Insider · CIK 0002063445
Tuan Nguyen
cfoofficer
Files at ABUS (Arbutus Biopharma Corp). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | ABUS Arbutus Biopharma Corp | DDisposition to issuer Common Shares | -48,081 | $5.00 | $240k | 111,882 | 6 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | MOption exercise Common Shares | +265,625 | $3.49 | $927k | 339,125 | 20 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | MOption exercise Common Shares | +27,475 | $4.39 | $121k | 366,600 | 20 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | FTax withholding Common Shares | -206,637 | $5.07 | $1.0M | 159,963 | 20 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | MOption exercise Stock Option (Right to Buy)derivative | -265,625 | $0.00 | $0 | 484,375 | 20 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | MOption exercise Stock Option (Right to Buy)derivative | -27,475 | $0.00 | $0 | 160,925 | 20 d ago |
| Feb 2, 2026 | ABUS Arbutus Biopharma Corp | AGrant or award Common Shares | +73,500 | $0.00 | $0 | 73,500 | Feb 2, 2026 |
| Feb 2, 2026 | ABUS Arbutus Biopharma Corp | AGrant or award Stock Option (Right to Buy)derivative | +188,400 | $0.00 | $0 | 188,400 | Feb 2, 2026 |
| Mar 31, 2025 | ABUS Arbutus Biopharma Corp | AGrant or award Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Apr 1, 2025 |
| Mar 31, 2025 | ABUS Arbutus Biopharma Corp | AGrant or award Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Mar 31, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.